HCV Treatment
Cochrane Review of Pegylated Interferon plus Ribavirin for Hepatitis C Treatment in People with HIV
- Details
- Category: HCV Treatment
- Published on Tuesday, 27 October 2009 12:49
- Written by Liz Highleyman
Pegylated interferon (Pegasys or PegIntron) plus ribavirin is an appropriate standard of care for HIV-HCV coinfected patients, with sustained virological response rates of 26% for hepatitis C virus (HCV) genotypes 1 or 4 and 57% for genotyes 2 or 3, according to a meta-analysis by the Cochrane Hepato-Biliary Group published in the September 2009 American Journal of Gastroenterology.
Blood Cholesterol May Increase after Successful Hepatitis C Treatment
- Details
- Category: HCV Treatment
- Published on Friday, 09 October 2009 14:01
- Written by Liz Highleyman
Blood levels of total and LDL cholesterol, which are typically lower among people with chronic hepatitis C virus (HCV) infection, may revert to dangerously high levels after successful interferon-based treatment, according to a study published in the October 2009 issue of Hepatology.
Statins May Increase Antiviral Activity of Hepatitis C Therapies and Delay Development of Resistance
- Details
- Category: HCV Treatment
- Published on Tuesday, 11 August 2009 14:01
- Written by Liz Highleyman
Statin drugs, typically used to manage high cholesterol, reduced hepatitis C virus (HCV) replication and increased the activity of interferon and directly-targeted anti-HCV agents in laboratory studies, and prevented development of resistance, according to a report in the July 2009 issue of Hepatology.
Pharmasset Selects Investigational HCV Polymerase Inhibitor PSI-879 for Preclinical Development
- Details
- Category: HCV Treatment
- Published on Friday, 09 October 2009 14:01
- Written by Pharmasset
Pharmasset, Inc. recently announced that it has chosen its experimental hepatitis C virus (HCV) polymerase inhibitor PSI-352879 (or PSI-879 for short) -- a purine nucleotide analog -- as a candidate for further preclinical development. PSI-879, as well as the company's other investigational nucleoside/nucleotide analogs, may potentially be suitable for use in combination regimens with other directly-targeted oral anti-HCV drugs now in the pipeline.
Older Genotype 3 Chronic Hepatitis C Patients Do Not Respond as Well to Interferon-based Therapy
- Details
- Category: HCV Treatment
- Published on Tuesday, 16 June 2009 13:41
- Written by HIVandHepatitis.com
Older age is associated with a lower likelihood of sustained response to pegylated interferon plus ribavirin in genotype 3 chronic hepatitis C patients, and people 50 years or older may benefit from longer treatment, according to a study presented at the recent Digestive Disease Week annual meeting (DDW 2009) in Chicago.
More Articles...
- Predictors of Sustained Treatment Response in HIV-HCV Coinfected Patients Receiving Routine Care
- DDW 2009: Vitamin B12 Levels May Help Predict Response to Interferon-based Therapy for Chronic Hepatitis C
- EASL 2009: Antiviral Agents with Activity against Both HIV and Hepatitis C Virus
- Active Injection Drug Users and Those on Opiate Substitution Treatment Can Have Good Hepatitis C Therapy Outcomes
Web Design and Development by